ArticleJAMA network open2023

Survival Outcomes in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy.

Jason A Mouabbi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.